Search

Your search keyword '"D'Andre, Stacy D."' showing total 8 results
Start Over Author "D'Andre, Stacy D." Journal journal of clinical oncology
8 results on '"D'Andre, Stacy D."'

1. Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial

Author

Liu, Joyce F., primary, Brady, Mark F., additional, Matulonis, Ursula A., additional, Miller, Austin, additional, Kohn, Elise C., additional, Swisher, Elizabeth M., additional, Cella, David, additional, Tew, William P., additional, Cloven, Noelle G., additional, Muller, Carolyn Y., additional, Bender, David P., additional, Moore, Richard G., additional, Michelin, David P., additional, Waggoner, Steven E., additional, Geller, Melissa A., additional, Fujiwara, Keiichi, additional, D'Andre, Stacy D., additional, Carney, Michael, additional, Alvarez Secord, Angeles, additional, Moxley, Katherine M., additional, and Bookman, Michael A., additional

Published
2022
Full Text
View/download PDF

3. Palbociclib (P) in patients (pts) with soft tissue sarcoma (STS) with CDK4 amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Author

Schuetze, Scott, primary, Rothe, Michael, additional, Mangat, Pam K., additional, Garrett-Mayer, Liz, additional, Meric-Bernstam, Funda, additional, Farrington, Laura Catherine, additional, Calfa, Carmen, additional, D'Andre, Stacy D., additional, Livingston, Michael B., additional, Thota, Ramya, additional, Marr, Alissa S., additional, von Mehren, Margaret, additional, Wentzel, Kristopher, additional, and Schilsky, Richard L., additional

Published
2021
Full Text
View/download PDF

4. Palbociclib (P) in patients (pts) with head and neck cancer (HNC) with CDKN2A loss or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Author

Pisick, Evan P., primary, Rothe, Michael, additional, Mangat, Pam K., additional, Garrett-Mayer, Liz, additional, Worden, Francis P., additional, Bauman, Jessica R., additional, Fu, Siqing, additional, Leidner, Rom S., additional, Balmanoukian, Ani Sarkis, additional, Calfa, Carmen, additional, Carrizosa, Daniel R., additional, D'Andre, Stacy D., additional, Nabell, Lisle, additional, Park, Min S., additional, Powell, Steven Francis, additional, Thota, Ramya, additional, and Schilsky, Richard L., additional

Published
2021
Full Text
View/download PDF

5. A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.

Author

Liu, Joyce F., primary, Brady, Mark F., additional, Matulonis, Ursula A., additional, Miller, Austin, additional, Kohn, Elise C., additional, Swisher, Elizabeth M., additional, Tew, William P., additional, Cloven, Noelle Gillette, additional, Muller, Carolyn, additional, Bender, David, additional, Moore, Richard G., additional, Michelin, David Paul, additional, Waggoner, Steven E., additional, Geller, Melissa Ann, additional, Fujiwara, Keiichi, additional, D'Andre, Stacy D., additional, Carney, Michael, additional, Secord, Angeles Alvarez, additional, Moxley, Katherine M., additional, and Bookman, Michael A., additional

Published
2020
Full Text
View/download PDF

7. Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with ERBB2 amplification or overexpression: Results from the TAPUR Study.

Author

Gupta, Ranju, primary, Garrett-Mayer, Elizabeth, additional, Halabi, Susan, additional, Mangat, Pam K., additional, D'Andre, Stacy D., additional, Meiri, Eyal, additional, Shrestha, Sagun, additional, Warren, Sasha L., additional, Ranasinghe, Shamika, additional, and Schilsky, Richard L., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results